1. Medtech Insight
  2. >>Geography
  3. >>Europe

Critical EU Authorities Meeting Next Week Could Be Make-Or-Break For Many Medtech Companies

 
• By Amanda Maxwell

The EU medtech industry is trying to put the brakes on the full application of the new Medical Devices and IVD Regulation as a logjam looms. What is it doing to succeed? And why is time running out?

EU Brussels

The EU trade association, MedTech Europe, believes that the future success, or otherwise, of the implementation of the EU Medical Devices and IVD Regulations (MDR and IVDR) hinges on decisions that national regulatory authorities and the European Commission will make following the sixth Medical Device Coordination Group (MDCG) meeting, scheduled for September 24 and 25.

MedTech Europe's members have been negotiating extensively with the competent authorities and the ministries of health of EU member states...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Europe

More from Geography

New Draft Guidance Clarifies FDA’s UDI Rules For Combination Products

 
• By Elizabeth Orr

The FDA has released draft guidance clarifying UDI rules for drug- and device-led combination products. The document specifies labeling requirements and makes recommendations to reduce confusion between UDIs and NDCs. Comments are being accepted until Sept. 24.

Medtronic’s ‘Strategic Expansion’ Into Remote Monitoring

 
• By Natasha Barrow

“The Corsano wearable strengthens Medtronic’s acute care and monitoring portfolio,” Marc De Martini, vice president at Medtronic, told Medtech Insight.

European Commission Asks For ‘Open Minds’ On Unified Drug/Device Research Pathway

 
• By Vibha Sharma

As the EU tests the feasibility of a radical “all-in-one” procedure for combined drug and IVD studies, sponsors are being urged to approach this novel framework with flexibility and openness.